Maze Therapeutics (MAZE) Stock Price, Quote, News & History | Benzinga

Maze Therapeutics Inc (MAZE) Stock Price, Quote, News & History

MAZENASDAQ

Trade with Public

Trade with Public

$27.18

-0.48-1.75%

At close: Aug 14, 5:00 PM EST

$27.18

N/A

After Hours: Aug 14, 4:00 PM EST

Earnings: Q2 2026 Earnings were released on Tue Aug 11th, after the market close

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$27.47

Close

$27.18

Volume / Avg.

230.65K / 568.20K

Day Range

$26.85 - $27.61

52 Wk Range

12.81 - 53.65

Market Cap

$1.51B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

45

Short Interest

11.51%

Days to Cover

15.88

Recent Maze Therapeutics, Inc. News

Crude Oil Moves Lower; Cintas Raises FY2026 Forecast

The Dow Jones index gained over 300 points, with the S&P 500 and NASDAQ also rising. Cintas Corp posted strong earnings and raised its forecast, while Sarepta Therapeutics and Braze Inc saw significant gains.

Avi Kapoor

Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings

US stocks rise with the Dow gaining over 300 points. Chewy shares jump 14%. Sarepta Therapeutics surges 29%. Oil down 2.1%, gold up 3.2%.

Avi Kapoor

Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829

Maze Therapeutics stock drops despite Phase 2 data showing uACR reductions in APOL1 kidney disease; analysts keep bullish targets.

Vandana Singh

This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Wall Street analysts have changed their outlook on top names, with new coverage and price targets. See the latest analyst ratings and opinions.

Avi Kapoor

This Strategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Analysts change outlook on top names, including initiations, upgrades, and downgrades. MSTR has a $175 price target and CROX has a Neutral rating.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-106.54M

Investing Cash Flow (TTM)

-292.50M

Financing Cash Flow (TTM)

337.14M

Free Cash Flow (TTM)

-106.84M

Capital Expenditure (TTM)

-302.00K

Net Change in Cash (TTM)

-61.90M

Analyst Trends and Forecast

8

Mar

1

Apr

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$1.16B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

73.33

PB Ratio (TTM)

3.39

Earnings Yield % (TTM)

-8.83%

Earnings Yield % (FWD)

-10.17%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$8.16

Company Debt

Total Debt

$38.96M

LT Debt

$38.96M

LT Debt Issuance (TTM)

$39.40M

LT Debt Repayment (TTM)

-

Total Cash

$202.64M

Debt to Equity

0.13

Issuance of Debt (TTM)

$39.40M

Repayment of Debt (TTM)

-

Key Statistics

Open

$27.47

Close

$27.18

Volume / Avg.

230.65K / 568.20K

Day Range

$26.85 - $27.61

52 Wk Range

12.81 - 53.65

Market Cap

$1.51B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

45

Short Interest

11.51%

Days to Cover

15.88

About

Sector

Health Care

Industry

Pharmaceuticals

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, ...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Maze Therapeutics (MAZE) stock?

A

You can purchase shares of Maze Therapeutics (NASDAQ:MAZE) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Maze Therapeutics (MAZE) competitors?

A

Other companies in Maze Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for Maze Therapeutics (MAZE) stock?

A

Maze Therapeutics has a consensus price target of $63.78.

Q

What is the current price for Maze Therapeutics (MAZE)?

A

The stock price for Maze Therapeutics (NASDAQ: MAZE) is $27.18 last updated August 14, 2026 at 4:00 PM EDT.

Q

Does Maze Therapeutics (MAZE) pay a dividend?

A

There are no upcoming dividends for Maze Therapeutics.

Q

When is Maze Therapeutics (NASDAQ:MAZE) reporting earnings?

A

Maze Therapeutics does not have any upcoming earnings scheduled.

Q

Is Maze Therapeutics (MAZE) going to split?

A

There is no upcoming split for Maze Therapeutics.

Q

What sector and industry does Maze Therapeutics (MAZE) operate in?

A

Maze Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.